Ixazomib effects and side effects

Ixazomib (ixazomib) is a proteasome inhibitor used to treat patients with multiple myeloma. Multiple myeloma is a cancer of the bone marrow that occurs when plasma cells grow out of control.

Ixazomib is available in capsule form. The U.S. Food and Drug Administration (FDA) has specifically approved ixazomib for use in combination with a thalidomide analog called lenalidomide (Revlimid) and the corticosteroid dexamethasone. Ixazomib is used in patients with multiple myeloma who have received at least one prior therapy.

Ixazomib works by preventing the breakdown of all "junk" proteins produced by myeloma cells, causing them to build up and kill the myeloma cells.

The most common side effects (occurring in more than one in five people) of ixazomib when taken with lenalidomide and dexamethasone are diarrhea, constipation, thrombocytopenia (low platelet count), neutropenia (low levels of neutrophils) , peripheral neuropathy (damage to the nerves in the hands and feet, causing tingling or numbness), nausea (feeling uncomfortable), peripheral edema (swelling, especially in the ankles and feet), vomiting, and nose and throat infections. Similar side effects were seen when lenalidomide and dexamethasone were used without ixazomib.

In addition, there are some more serious side effects that require vigilance, such as posterior reversible encephalopathy syndrome (PRES), peripheral neuropathy, pneumonia, herpes zoster, and hypokalemia. If these symptoms occur, seek medical attention immediately.

Please note that although ixazomib has shown some efficacy in the treatment of multiple myeloma, its side effects cannot be ignored. Patients should strictly follow the doctor's instructions when using it, and pay close attention to their physical condition. If they have any discomfort, they should seek medical consultation in time.